REC-2282

REC-2282 · Recursion Pharmaceuticals Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for REC-2282, covering 2025-10-07 to 2025-10-07. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas [Phase 2, Phase 3]

See pricing